KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Research & Development: 2017-2025

Historic Research & Development for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $4.5 million.

  • Aquestive Therapeutics' Research & Development fell 14.03% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 3.63%. This contributed to the annual value of $20.3 million for FY2024, which is 54.76% up from last year.
  • Aquestive Therapeutics' Research & Development amounted to $4.5 million in Q3 2025, which was up 10.35% from $4.1 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Research & Development high stood at $5.9 million for Q1 2024, and its period low was $2.9 million during Q4 2023.
  • Over the past 3 years, Aquestive Therapeutics' median Research & Development value was $4.2 million (recorded in 2024), while the average stood at $4.3 million.
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 34.90% in 2021, then soared by 70.26% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Research & Development (Quarterly) stood at $4.4 million in 2021, then fell by 2.77% to $4.3 million in 2022, then plummeted by 32.49% to $2.9 million in 2023, then spiked by 70.26% to $4.9 million in 2024, then dropped by 14.03% to $4.5 million in 2025.
  • Its Research & Development stands at $4.5 million for Q3 2025, versus $4.1 million for Q2 2025 and $5.4 million for Q1 2025.